Medicare Advantage’s Discipline Era — and Why the Final Rate Notice Matters More Than It Appears

Several years ago, during a budget review at a Medicare Advantage organization I led, our finance team flagged a familiar problem: medical costs were rising faster than projected revenue. On paper, the solution was straightforward — add copays, trim a transportation benefit that helped seniors get to appointments, narrow a handful of provider contracts, and expand prior authorization for certain services.

None of those changes felt dramatic.

But taken together, they subtly reshaped how members experienced care. Access became slightly harder. Choices slightly narrower. Friction slightly higher.

That is what financial pressure looks like in Medicare Advantage — not sudden cuts, but a steady recalibration that beneficiaries feel long before policymakers do.

When the Centers for Medicare & Medicaid Services released its recent Advance Notice suggesting Medicare Advantage revenues may remain largely flat heading into 2027, many outside the industry viewed it as technical fine print. Within the system, it was understood as a turning point.

For more than a decade, Medicare Advantage benefited from structural tailwinds: enrollment growth as seniors increasingly chose private plans, rate increases that generally tracked medical inflation, and financial flexibility that supported expanded benefits and care coordination. Growth helped absorb inefficiencies and postponed difficult tradeoffs.

That cushion has already been thinning.

Over the past two years, plans have begun absorbing the impact of the V28 risk adjustment model—a recalibration intended to better align payments with true clinical complexity. While the policy goals are sound, the operational reality has been a meaningful reduction in risk revenue across much of the industry, arriving at the same moment that medical costs have accelerated. For many organizations, V28 effectively functioned as an early tightening of rates, forcing benefit redesigns, cost controls, and provider renegotiations well before any formal flattening of base payments.

Layering flat revenue on top of that shift compounds the pressure.

Labor shortages continue to drive wages higher. Hospital consolidation has strengthened provider pricing power. Pharmaceutical spending — particularly for specialty and chronic disease therapies — remains elevated. In real terms, flat funding in this environment is not neutral. It represents a contraction in the resources available to deliver coordinated, high-quality care.

This transition reflects Medicare Advantage reaching maturity. As the program becomes the dominant form of Medicare coverage, greater fiscal discipline is inevitable and appropriate. Growth alone can no longer mask inefficiency. Operational rigor must replace momentum.

But the pace of adjustment matters.

Medicare Advantage was designed to correct the structural weaknesses of fee-for-service Medicare by promoting coordinated care, preventive services, and accountability for total cost and outcomes. Its success has depended not only on cost control but on sustained investment in clinical programs, technology, and provider partnerships that keep seniors healthier and out of hospitals.

When financial pressure intensifies — especially abruptly — those investments are often the first to be questioned.

The impact rarely shows up as headline benefit cuts. Instead, it emerges gradually through narrower networks, tighter utilization management, and quieter reductions in supplemental benefits such as dental, vision, transportation, and in-home supports. Each step may seem modest in isolation. Together, they reshape access and experience for millions of seniors.

Provider relationships will tighten as well. With less financial headroom, routine rate increases become harder to absorb, intensifying negotiations around risk sharing and performance expectations. Some provider groups may narrow participation or exit Medicare Advantage altogether, potentially reducing continuity and choice in certain markets.

Inside health plans, the discipline era is already visible. Hiring slows. Investment hurdles rise. Automation accelerates. Leaders are forced to distinguish clearly between initiatives that generate real clinical and financial value and those sustained by the easier economics of the past. Over time, this can strengthen organizations. In the short term, abrupt compression risks privileging near-term cost cutting over longer-term system improvement.

Investors are adjusting expectations accordingly. Medicare Advantage remains attractive, but success increasingly depends on scale, execution, and differentiated care models rather than rapid expansion. Smaller and regional plans face mounting consolidation pressure as fixed costs consume a greater share of flatter revenues.

None of this suggests Medicare Advantage is broken. It reflects a program entering the phase every major healthcare system eventually reaches—where sustainability, outcomes, and efficiency replace growth as the central measures of success.

Still, there is an important difference between healthy fiscal discipline and destabilizing contraction.

A meaningful upward calibration in the Final Notice — one that more closely reflects underlying medical inflation and the cumulative impact of recent policy shifts such as V28 — would not reverse the program’s maturation. It would simply allow the transition to unfold in a more stable and predictable way.

Well-calibrated rates help preserve beneficiary access, maintain provider participation, and sustain investments that prevent hospitalizations, manage chronic disease, and improve outcomes. Under-calibration risks accelerating the quiet erosion of benefits and networks in ways that ultimately undermine the value Medicare Advantage was created to deliver.

Critics rightly argue that Medicare Advantage must continue improving efficiency, strengthening risk adjustment integrity, and reducing administrative waste. Discipline is essential. But discipline works best when grounded in the real cost of delivering care to an increasingly complex and aging population.

Medical inflation is not theoretical. Workforce shortages are not temporary. Clinical complexity continues to rise—not to mention the aggressiveness with which providers are using artificial intelligence to upcode care (and making it more expensive). Ignoring these realities risks shifting cost pressure downstream in ways that harm access rather than improving value.

The challenge for policymakers is balance: encouraging rigor without unintentionally weakening a program that now serves the majority of Medicare beneficiaries.

Regardless of the final number, Medicare Advantage has entered its discipline era. Growth will no longer compensate for inefficiency. Leaders will be defined by their ability to deliver better outcomes at sustainable cost.

But thoughtful rate calibration can determine whether this transition strengthens the program — or strains it unnecessarily.

The era of easy money is over. The next chapter must be about durable value. The Final Notice offers an opportunity to guide that evolution wisely.

Photo: designer491, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.